Ayming for the best version of Spanish biotechnology
Biocompanies are synonymous of innovation and transformation, as they have always outlined each area of their activity in order to concentrate talent, new technologies and research
If there is a sector in Spain that is aware about the big differences are made by small details, it is the biotechnology sector. Biocompanies are synonymous of innovation and transformation, as they have always outlined each area of their activity in order to concentrate talent, new technologies and research, among other strategic areas that allow them to lead in their respective markets.
Biotechnology invested more than 940 million euros in R&D during 2019, according to the latest ASEBIO Report. An innovation that determines the progress, safety and quality of life of our society, solving challenges that only biotechnology can respond to.
A transforming role that confirms data such as is the sector that invests the most in R&D in relation to its production, with 5.63% of investment, again above sectors such as pharmaceuticals. This trend is also reflected in comparison with companies in other sectors, as they are the first in terms of R&D investment intensity, only after the services and education sectors.
Innovation in biotechnology is also synonymous with public and private collaboration, a very positive symptom of the coming scenario, clearly with a view to Europe.
According to the latest data from the National Statistics Institute (INE), 42.3% of the funds allocated to biotechnology R&D in the country come from the public administration, followed by companies, with 41.4% for their part.
For all these reasons, it is necessary to promote the necessary impulses and incentives so that innovation continues to advance in this sector, in order to recover from the impact caused by the current pandemic that we are still experiencing.
The Next Generation EU Funds structured in the Spain Can Plan, with 140,000 million euros, will allow the sector to transform through specific programs in sustainability, digitalization, or even its social identity. Let's remember that this sector is the second with the second highest percentage of researchers over the total number of employees, highlighting the importance for Spain not only to continue to advance, but also to maintain its quality and standards.
These funds are key to face the current context, in which recovery marks the most immediate future, but also in which business competitiveness marks the day to day.
Only in Science and Innovation, in 2021 we will have an investment of more than 2,400 million euros in grants and subventions, channeled through the CDTI, the State Research Agency, or the Carlos III Health Institute in Madrid. This unprecedented funding is complemented with other calls for financial support, such as the one promoted by SEPIDES, the FAIIP, which is endowed with 600 Million Euros for the industrial development of the sector.
Opportunities for which it will be necessary to provide solvency, accuracy and transparency in each application and project. Historically, our country barely takes advantage of 34% of the European funds it receives, and at Ayming we believe it is time for this to change. We propose an advice based on transparency and above all, technical rigour.
We want the sector to continue to link science and progress. No doubts about it: Further Together.